Predictors of drug survival of biologic therapies in psoriasis patients


Zorlu O., BÜLBÜL BAŞKAN E. , YAZİCİ S. , SIĞIRLI D. , BUDAK F. , SARICAOĞLU H. , ...More

JOURNAL OF DERMATOLOGICAL TREATMENT, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume:
  • Publication Date: 2020
  • Doi Number: 10.1080/09546634.2020.1763240
  • Title of Journal : JOURNAL OF DERMATOLOGICAL TREATMENT
  • Keywords: Anti-TNF, biologics, HLA-Cw6, psoriasis, CLINICAL-RESPONSE, OBSERVATIONAL COHORT, BRITISH ASSOCIATION, USTEKINUMAB, POLYMORPHISMS, ETANERCEPT, ADALIMUMAB, HLA-C-ASTERISK-06, ANTIBODIES, ALLELE

Abstract

Introduction: We aimed to investigate the clinical, immunological, and genetic factors affecting the response to anti-TNF alpha (tumor necrosis factor-alpha) and interleukin-12/23 therapies and drug survivals. Methods: A total of 180 patients were divided into two groups: 89 patients who used at least two biologic agents, with the initial biologic agent used less than 12 months (group A), and 91 biologic-naive patients who have been receiving a single biologic agent for more than 12 months (group B). ELISA (enzyme-linked immunosorbent assay) was used to analyze anti-drug antibodies (ADAs) in blood samples. Clinical data of the patients were retrospectively analyzed. HLA-SSO (sequence-specific oligonucleotide) Typing Kits were used for HLA-C typing. IBM SPSS v.21 was used for statistical analysis. Results: Infliximab had the longest drug survival as the first biologic agent in group A (p = .015). Etanercept had the lowest ADA count compared to the other anti-TNF agents (p = .001). HLA-Cw6 negativity, late-onset psoriasis, smoking and alcohol use were determined to be risk factors for treatment failure in group A. HLA-Cw6 was found to be associated with type I psoriasis (p = .000). Conclusions: Although our study is retrospective of a relatively low number of patients, this is a preliminary study focusing on two different patient populations based on therapy response.